Cargando…

First‐in‐human study of deucravacitinib: A selective, potent, allosteric small‐molecule inhibitor of tyrosine kinase 2

This randomized, double‐blind, single‐ and multiple‐ascending dose study assessed the pharmacokinetics (PKs), pharmacodynamics, and safety of deucravacitinib (Sotyktu™), a selective and potent small‐molecule inhibitor of tyrosine kinase 2, in 100 (75 active, 25 placebo) healthy volunteers (NCT025346...

Descripción completa

Detalles Bibliográficos
Autores principales:	Catlett, Ian M., Aras, Urvi, Hansen, Lars, Liu, Yali, Bei, Di, Girgis, Ihab G., Murthy, Bindu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9841305/ https://www.ncbi.nlm.nih.gov/pubmed/36325947 http://dx.doi.org/10.1111/cts.13435

Ejemplares similares

Pharmacokinetics and Safety of the Tyrosine Kinase 2 Inhibitor Deucravacitinib in Healthy Chinese Subjects
por: Jing, Shan, et al.
Publicado: (2023)

Lack of Electrocardiographic Effects of Deucravacitinib in Healthy Subjects
por: Chimalakonda, Anjaneya, et al.
Publicado: (2022)

Selectivity Profile of the Tyrosine Kinase 2 Inhibitor Deucravacitinib Compared with Janus Kinase 1/2/3 Inhibitors
por: Chimalakonda, Anjaneya, et al.
Publicado: (2021)

Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase II, Randomized, Double‐Blind, Placebo‐Controlled Trial
por: Morand, Eric, et al.
Publicado: (2022)

Deucravacitinib: First Approval
por: Hoy, Sheridan M.
Publicado: (2022)

Deucravacitinib for the Treatment of Psoriatic Disease
por: Lé, Ana Maria, et al.
Publicado: (2022)

Safety, pharmacokinetics and pharmacodynamics of branebrutinib (BMS‐986195), a covalent, irreversible inhibitor of Bruton's tyrosine kinase: Randomised phase I, placebo‐controlled trial in healthy participants
por: Catlett, Ian M., et al.
Publicado: (2020)

The efficacy and safety of tyrosine kinase 2 inhibitor deucravacitinib in the treatment of plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials
por: Qiu, Jingyue, et al.
Publicado: (2023)

Deucravacitinib, a tyrosine kinase 2 pseudokinase inhibitor, protects human EndoC-βH1 β-cells against proinflammatory insults
por: Dos Santos, Reinaldo S., et al.
Publicado: (2023)

Deucravacitinib for the treatment of psoriatic arthritis: the evidence so far
por: Martins, Ana, et al.
Publicado: (2023)

Clinical Utility of Deucravacitinib for the Management of Moderate to Severe Plaque Psoriasis
por: Jin, Joy Q, et al.
Publicado: (2023)

Successful treatment of refractory subacute cutaneous lupus erythematosus with deucravacitinib
por: Bouché, Nicole, et al.
Publicado: (2023)

Effectiveness and Safety of Deucravacitinib for the Management of Psoriasis: A Review of the Current Literature
por: Potestio, Luca, et al.
Publicado: (2023)

New, potent, small molecule agonists of tyrosine kinase receptors attenuate dry eye disease
por: Yu, Zhiyuan, et al.
Publicado: (2022)

Allosteric Communication across the Native and Mutated KIT Receptor Tyrosine Kinase
por: Laine, Elodie, et al.
Publicado: (2012)

Rapid hair regrowth in an alopecia universalis patient with deucravacitinib: A case report
por: Oliel, Sarah, et al.
Publicado: (2023)

Small molecule inhibition of Axl receptor tyrosine kinase potently suppresses multiple malignant properties of glioma cells
por: Vouri, Mikaella, et al.
Publicado: (2015)

Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 Trial
por: Thaçi, Diamant, et al.
Publicado: (2022)

Ellagic Acid and Its Metabolites as Potent and Selective Allosteric Inhibitors of Liver Pyruvate Kinase
por: Battisti, Umberto Maria, et al.
Publicado: (2023)

The Allosteric Site on SHP2’s Protein Tyrosine Phosphatase Domain is Targetable with Druglike Small Molecules
por: Marsh-Armstrong, Brennan, et al.
Publicado: (2018)

Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis
por: Mease, Philip J, et al.
Publicado: (2022)

Elucidation of a four-site allosteric network in fibroblast growth factor receptor tyrosine kinases
por: Chen, Huaibin, et al.
Publicado: (2017)

Novel Anthraquinone-based Derivatives as Potent Inhibitors for Receptor Tyrosine Kinases
por: Stasevych, M., et al.
Publicado: (2015)

β‐Hydroxyisovalerylshikonin Is a Novel and Potent Inhibitor of Protein Tyrosine Kinases
por: Hashimoto, Sachiko, et al.
Publicado: (2002)

Tyrosine Kinase Inhibitors Display Potent Activity against Cryptosporidium parvum
por: Nava, Maria G., et al.
Publicado: (2022)

Small molecule tyrosine kinase inhibitors in pancreatic cancer
por: Gupta, Sachin, et al.
Publicado: (2008)

Matching-Adjusted Indirect Comparison of the Long-Term Efficacy of Deucravacitinib Versus Adalimumab for Moderate to Severe Plaque Psoriasis
por: Armstrong, April W., et al.
Publicado: (2023)

Discovery of a Potent and Selective DDR1 Receptor Tyrosine Kinase Inhibitor
por: Kim, Hyung-Gu, et al.
Publicado: (2013)

Novel Small-Molecule AMP-Activated Protein Kinase Allosteric Activator with Beneficial Effects in db/db Mice
por: Zhang, Li-Na, et al.
Publicado: (2013)

Fluorescence Polarization Screening Assays for Small Molecule Allosteric Modulators of ABL Kinase Function
por: Grover, Prerna, et al.
Publicado: (2015)

Discovery of Non-peptide Small Molecule Allosteric Modulators of the Src-family Kinase, Hck
por: Dorman, Heather R., et al.
Publicado: (2019)

New Series of Potent Allosteric Inhibitors of Deoxyhypusine Synthase
por: Tanaka, Yuta, et al.
Publicado: (2020)

Correction to: Matching-Adjusted Indirect Comparison of the Long-Term Efficacy of Deucravacitinib Versus Adalimumab for Moderate to Severe Plaque Psoriasis
por: Armstrong, April W., et al.
Publicado: (2023)

Short-, Mid-, and Long-Term Efficacy of Deucravacitinib Versus Biologics and Nonbiologics for Plaque Psoriasis: A Network Meta-Analysis
por: Armstrong, April W., et al.
Publicado: (2023)

Fast and Sensitive Bioanalytical Method for the Determination of Deucravacitinib in Human Plasma Using HPLC-MS/MS: Application and Greenness Evaluation
por: Mahesh, Pottabattula, et al.
Publicado: (2023)

Inhibition of receptor tyrosine kinase signalling by small molecule agonist of T-cell protein tyrosine phosphatase
por: Mattila, Elina, et al.
Publicado: (2010)

Effects of rifampin on the pharmacokinetics and pharmacodynamics of milvexian, a potent, selective, oral small molecule factor XIa inhibitor
por: Perera, Vidya, et al.
Publicado: (2022)

Masitinib (AB1010), a Potent and Selective Tyrosine Kinase Inhibitor Targeting KIT
por: Dubreuil, Patrice, et al.
Publicado: (2009)

Correction to Discovery of a Potent and Selective DDR1 Receptor Tyrosine Kinase Inhibitor
por: Kim, Hyung-Gu, et al.
Publicado: (2014)

Identification of a Novel Series of Potent TrkA Receptor Tyrosine Kinase Inhibitors
por: Raeppel, Stéphane L., et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_a8vkj6577e84qvpgdigl34hoer